{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:17:49Z","timestamp":1774675069764,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["777389"],"award-info":[{"award-number":["777389"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40290-020-00373-6","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T10:09:11Z","timestamp":1612433351000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The conect4children (c4c) Consortium: Potential for Improving European Clinical Research into Medicines for Children"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-8656","authenticated-orcid":false,"given":"Mark A.","family":"Turner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidrun","family":"Hildebrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo M.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenna","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gis","family":"Hankard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fedele","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Nobels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabah","family":"Attar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Claverol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-3663","authenticated-orcid":false,"given":"Begonya","family":"Nafria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"373_CR1","unstructured":"EMA. The European Paediatric Initiative: history of the paediatric regulation. 2007. https:\/\/www.ema.europa.eu\/en\/documents\/other\/european-paediatric-initiative-history-paediatric-regulation_en.pdf. Accessed 13 July 2020."},{"key":"373_CR2","unstructured":"EMA. Paediatric investigation plans. 2020. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/paediatric-medicines\/paediatric-investigation-plans. Accessed 13 July 2020."},{"key":"373_CR3","unstructured":"EC. State of Paediatric Medicines in the EU: 10 years of the EU Paediatric Regulation. 2017. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/paediatrics\/docs\/2017_childrensmedicines_report_en.pdf. Accessed 13 July 2020."},{"key":"373_CR4","volume-title":"Envisioning a transformed clinical trials enterprise in the United States: establishing an agenda for 2020","author":"NE Weisfeld","year":"2012","unstructured":"Weisfeld NE, English RA, Claiborne AB. Envisioning a transformed clinical trials enterprise in the United States: establishing an agenda for 2020. Washington: National Academies Press; 2012."},{"issue":"11","key":"373_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/archdischild-2015-310001","volume":"101","author":"P Lepola","year":"2016","unstructured":"Lepola P, Needham A, Mendum J, Sallabank P, Neubauer D, de Wildt S. Informed consent for paediatric clinical trials in Europe. Arch Dis Child. 2016;101(11):1017\u201325. https:\/\/doi.org\/10.1136\/archdischild-2015-310001.","journal-title":"Arch Dis Child."},{"issue":"Suppl 10","key":"373_CR6","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1002\/jcph.1284","volume":"58","author":"J van den Anker","year":"2018","unstructured":"van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental changes in pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2018;58(Suppl 10):S10-s25. https:\/\/doi.org\/10.1002\/jcph.1284.","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"373_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/pr.2016.221","volume":"81","author":"RM Ward","year":"2017","unstructured":"Ward RM, Benjamin D, Barrett JS, Allegaert K, Portman R, Davis JM, et al. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. Pediatr Res. 2017;81(5):692\u2013711. https:\/\/doi.org\/10.1038\/pr.2016.221.","journal-title":"Pediatr Res."},{"key":"373_CR8","unstructured":"IMI2. https:\/\/www.imi.europa.eu. Accessed 25 Oct 2020."},{"key":"373_CR9","unstructured":"c4c. https:\/\/conect4children.org. Accessed 25 Oct 2020."},{"key":"373_CR10","unstructured":"PENTA. https:\/\/penta-id.org. Accessed 25 Oct 2020."},{"key":"373_CR11","unstructured":"PRINTO. https:\/\/printo.it\/. Accessed 25 Oct 2020."},{"key":"373_CR12","unstructured":"Treat-NMD. https:\/\/treat-nmd.org. Accessed 25 Oct 2020."},{"key":"373_CR13","unstructured":"Network ECFSCT. https:\/\/www.ecfs.eu\/ctn. Accessed 25 Oct 2020."},{"key":"373_CR14","unstructured":"SIOPE. https:\/\/siope.eu. Accessed 25 Oct 2020."},{"key":"373_CR15","unstructured":"Neuropsychopharmacology ECo. https:\/\/www.ecnp.eu\/research-innovation\/ECNP-networks\/List-ECNP-Networks\/Child-and-adolescent-neuropsychopharmacology. Accessed 25 Oct 2020."},{"key":"373_CR16","unstructured":"Diseases EJPoR. https:\/\/www.ejprarediseases.org. Accessed 25 Oct 2020."},{"key":"373_CR17","unstructured":"EMA. https:\/\/www.ema.europa.eu\/en\/partners-networks\/networks\/european-network-paediatric-research-european-medicines-agency-enpr-ema. Accessed 25 Oct 2020."},{"issue":"8","key":"373_CR18","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.clinthera.2019.07.018","volume":"41","author":"DL Michaels","year":"2019","unstructured":"Michaels DL, Lamberti MJ, Pe\u00f1a Y, Kunz BL, Getz K. Assessing biopharmaceutical company experience with patient-centric initiatives. Clin Ther. 2019;41(8):1427\u201338. https:\/\/doi.org\/10.1016\/j.clinthera.2019.07.018.","journal-title":"Clin Ther."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-020-00373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40290-020-00373-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-020-00373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T10:20:08Z","timestamp":1616149208000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40290-020-00373-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1007\/s40290-020-00373-6","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"15 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Collaborative Network for European Clinical Trials for Children (conect4children or c4c) is an action under the Innovative Medicines Initiative 2 (IMI2) Joint Understanding (), Grant Agreement 777389. The open access fee was paid by the University of Liverpool.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All the authors are associated with the c4c project because their employers are Beneficiaries of the c4c Consortium. Cheng is an employee of Johnson and Johnson; Hildebrand is an employee of Bayer AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MAT drafted the paper and contributes to the leadership of c4c. HH reviewed the paper and contributes to the leadership of c4c. RMF reviewed the paper and contributes to the leadership of c4c. SdW reviewed the paper and contributes to the leadership of c4c. FM reviewed the paper and contributes to the leadership of c4c. RH reviewed the paper and contributes to the leadership of c4c. RL reviewed the paper and contributes to the leadership of c4c. FB reviewed the paper and contributes to the leadership of c4c. PN reviewed the paper and contributes to the leadership of c4c. KC reviewed the paper and contributes to the leadership of c4c. SA reviewed the paper and contributes to the leadership of c4c. PR reviewed the paper and contributes to the leadership of c4c. FR reviewed the paper and contributes to the leadership of c4c. JC reviewed the paper and contributes to the leadership of c4c. BN reviewed the paper and contributes to the leadership of c4c. CG reviewed the paper and contributes to the leadership of c4c.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}